This current study is the first to report the effect of PEG-INF-α based therapy on serum concentrations of activin-A, activin-B, AFRI, BFRI, ASFRI, and follistatin in patients diagnosed with CHC. This evidence concerns the gene FST and cryohydrocytosis.